Middle East Pharmaceutical Reports SAR 26.9M Net Profit in Three Months 2026
AVALON PHARMA 4016.SA | 0.00 |
On 2026-05-06 08:17:13 (Saudi Time), Middle East Pharmaceutical Industries Co. announced its Interim financial results for the three months ended on March 31, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 130.13 | 97.36 | 33.658 | 137.52 | -5.373 |
| Gross Profit (Loss) | 80.62 | 60.27 | 33.764 | 90.47 | -10.887 |
| Operational Profit (Loss) | 30.72 | 22.3 | 37.757 | 46.84 | -34.415 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 26.9 | 19.4 | 38.659 | 44.52 | -39.577 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 27.61 | 19.4 | 42.319 | 44.91 | -38.521 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Shareholders Equity (after Deducting Minority Equity) | 417.45 | 387.61 | 7.698 |
| Profit (Loss) per Share | 1.34 | 0.97 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
Sales increased 33.658% YoY to SAR 130.13 million, driven by strong growth in the Private segment (+38.7%) through new customer onboarding, higher sell-out rates, targeted trade activation initiatives, and expansion in high-value segments like Specialized Care and Dermatology, while Public segment revenues rose 28.6% from tender awards. Net profit grew 38.659% YoY to SAR 26.9 million, supported by the strong revenue growth and improved net profit margin from 19.9% to 20.7%.
Quarter-on-Quarter Performance Drivers
QoQ revenue declined 5.37% to SAR 130.13 million due to seasonal demand normalization following a historically stronger Q4 2025. Net profit fell 39.58% to SAR 26.9 million, primarily driven by the sequential revenue decline and higher operating expenses from increased commercial investments to support business scalability and future market share growth.
Other Items
The external auditor issued an unmodified conclusion for the interim financial statements. The auditor noted that the comparative period financial statements for March 31, 2025 were audited by another auditor who also expressed an unmodified opinion. Total shareholders equity increased 7.698% to SAR 417.45 million, while earnings per share improved to SAR 1.34 compared to SAR 0.97 in the prior year period.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=94993&anCat=1&cs=4016&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/25633_5507_2026-05-05_22-36-03_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.